Background: Surgical resection of metastasis can be integrated in the management of metastatic renal cell carcinoma (mRCC) as it can contribute to delay disease progression and improve survival.
Objective: This study assessed the impact of complete metastasectomy in mRCC patients using real-world pan-Canadian data.
Design, Setting And Participants: The Canadian Kidney Cancer information system (CKCis) database was used to select patients who were diagnosed with mRCC between January 2011 and April 2019. To minimize selection bias, each patient having received a complete metastasectomy was matched with up to 4 patients not treated with metastasectomy.
Outcome Measurements And Statistical Analysis: Overall survival (OS) was calculated from the date of metastasectomy or selection, to death from any cause. A Cox proportional hazards model was used to assess the impact of the metastasectomy while adjusting for potential confounding variables.
Results: A total of 229 patients undergoing complete metastasectomy were matched with 803 patients not treated with metastasectomy. After matching, baseline characteristics were well balanced between groups. After 12 months, the proportion of patients that were still alive was 96.0% and 89.8% in the complete metastasectomy and its matched group, respectively; the 5-year OS were 63.2% and 51.4%, respectively. Multivariate analysis performed in the matched cohort revealed that patients who underwent complete metastasectomy had a lower risk of mortality compared to patients who did not undergo metastasectomy (hazard ratio: 0.41, 95% confidence interval:0.27-0.63).
Conclusion: Our study found that patients who underwent complete metastasectomy have a longer overall survival and a longer time to initiation of targeted therapy compared to patients not receiving metastasectomy. These findings should support aggressive resection of metastasis in selected patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.urolonc.2020.07.021 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Later lines of systemic therapy in patients with metastatic colorectal cancer: real-world data from a setting with barriers to access cancer therapies.
J Gastrointest Oncol
December 2024
Division of Gastrointestinal Medical Oncology, Oncoclinicas, São Paulo, Brazil.
Background: Regorafenib and trifluridine/tipiracil (TFD/TPI) are oral systemic therapies with survival benefit in chemorefractory metastatic colorectal cancer (mCRC) patients, but they are not widely available worldwide. We aimed to evaluate the treatment patterns and outcomes of patients with limited access to these drugs.
Methods: Retrospective study involving 510 patients with mCRC who were treated at five different centers in Brazil, from January 2011 to December 2019.
Advancements in prognostic factors and survival outcomes following pulmonary metastasectomy for head and neck cancers.
Kardiochir Torakochirurgia Pol
December 2024
Department of Cardiothoracic and Vascular Surgery, Westpfalz Klinikum, Kaiserslautern, Germany.
Surgical treatment of lung metastases originating from head and neck tumors has shown favorable outcomes with low incidence of complications and mortality. This study aims to investigate survival and prognostic factors following pulmonary metastasectomy for head and neck cancers. A comprehensive review of the literature was conducted through the Medline database, focusing on English-language studies related to surgical treatment of lung metastases from head and neck cancers.
View Article and Find Full Text PDFOligometastatic Esophagogastric Cancer: Does It Exist and How Do We Treat It?
Curr Oncol Rep
January 2025
Department of Surgery, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Purpose Of The Review: This narrative review aims to provide an overview of recently completed randomized trials and expert consensus recommendations, and their implications for clinical practice and future trial design in patients with de-novo esophagogastric oligometastatic disease (OMD).
Recent Findings: The IKF-575/RENAISSANCE phase III trial showed no significant overall survival difference between systemic therapy alone and systemic therapy combined with local therapy for patients with gastric or gastroesophageal junction cancer and de-novo OMD, except for patients with retroperitoneal lymph node metastases only. The ESO-Shanghai 13 phase II trial demonstrated superiority of adding local therapy to systemic therapy for progression-free and overall survival in oligometastatic esophageal squamous cell carcinoma.
Adjuvant therapy in renal cell carcinoma (RCC): progress, at last.
Transl Cancer Res
November 2024
Division of Hematology and Oncology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.
In the United States, there is expected to be about 82,000 cases of renal cell carcinoma (RCC) in 2024. At diagnosis, approximately 65% of patients with RCC will have disease localized to the kidney. For decades, the standard of care for patients with localized RCC has been surgery, which is often curative, followed by radiographic surveillance.
View Article and Find Full Text PDFThe Role of Pulmonary Metastasectomy for Non-Primary Lung Cancer: Umbrella Review of Meta-Analyses.
J Surg Oncol
December 2024
Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Background And Objectives: Due to heterogeneous characteristics of primary cancers, the efficacy of pulmonary metastasectomy (PM) in nonprimary lung cancers has not been investigated. This study aims to investigate the clinical outcomes of PM for non-primary lung cancer.
Methods: A systematic search for meta-analyses on PM for nonprimary lung cancers was conducted, encompassing publications up to January 3, 2024.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!